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ABSTRACT:
PIK3CA mutations are frequently diagnosed in diverse cancers and may predict 
response to PI3K/AKT/mTOR inhibitors. It remains unclear whether they are 
associated with other characteristics. We analyzed characteristics and outcome of 
90 consecutive patients with diverse advanced tumors and PIK3CA mutations and 
180 wild-type PIK3CA controls matched by tumor type, gender, and age referred to 
the Clinical Center for Targeted Therapy. PIK3CA and MAPK mutations (KRAS, NRAS, 
and BRAF) were analyzed using polymerase chain reaction-based DNA sequencing. 
The most frequent PIK3CA mutations were E545K (31/90, 34%), E542K (16/90, 
18%) in exon 9, and H1047R (20/90, 22%) in exon 20. PIK3CA mutations compared 
to wild-type PIK3CA were associated with simultaneous KRAS (p=0.047) and 
MAPK mutations (p=0.03), but only MAPK mutations were confirmed as having an 
independent association in multivariate analysis.   Rates of lung, bone, liver and brain 
metastases were similar in PIK3CA-mutant and wild-type patients.  Patients with 
PIK3CA mutations treated on trials with PI3K/AKT/mTOR inhibitors had a higher 
partial/complete response (PR/CR) rate than wild-type PIK3CA patients treated 
with their best phase I therapy (10/56, 18% vs. 12/152, 8%; p=0.045), but not 
a prolonged progression-free survival. Patients with H1047R PIK3CA mutations 
had a higher PR/CR rate with PI3K/AKT/mTOR inhibitors compared to wild-type 
PIK3CA patients treated with their best phase I therapy (6/16, 38% vs. 12/152, 8%; 
p=0.003). In conclusion, PIK3CA mutations in diverse cancers were not associated 
with clinical characteristics, but were correlated with MAPK mutations. PIK3CA 
mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/
AKT/mTOR pathway inhibitors.
INTRODUCTION
PIK3CA mutations frequently occur in diverse 
cancers and are associated with constitutive activation 
of the PI3K/AKT/mTOR pathway.[1-5] In addition, 
PIK3CA mutations predicted sensitivity to PI3K/AKT/
mTOR inhibitors in multiple tumor types in preclinical 
and early clinical experiments.[1, 2, 5-12] A seminal 
question is whether PIK3CA mutations are associated with 
a distinct phenotypic taxonomy. Retrospective studies in 
colorectal cancer demonstrated that PIK3CA mutations in 
exon 20 encoding for the kinase domain, but not in exon 
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9 encoding for the helical domain, are associated with 
resistance to EGFR-targeting monoclonal antibodies.
[13] In addition, our group reported that, regardless of 
histology, PIK3CA mutations often coexist with mitogen-
activated protein kinase (MAPK) mutations, such as 
mutated KRAS, NRAS, and BRAF.[14] A partial answer to 
the question posed about the relationship between PIK3CA 
mutations and specific subtypes of cancer is generally that 
different cancers seem to have different types of PIK3CA 
mutations and associations with still other mutations.[15] 
For example, in colorectal cancer PIK3CA mutations in 
exon 9, but not exon 20, trended toward an association 
with KRAS mutations, whereas only PIK3CA exon 20 
mutations were associated with KRAS mutations in 
ovarian cancer.[13, 16] Other oncogenic mutations have 
also been correlated with clinical characteristics and 
outcome. For example patients with advanced cancers and 
BRAF mutations have less soft tissue, retroperitoneal, lung 
metastases and more brain metastases.[17]  In colorectal 
cancer, BRAF mutations predicted poor outcome and 
KRAS mutations were associated with lung metastases.
[13, 18] We investigated characteristics and outcomes of 
patients with advanced cancers with and without PIK3CA 
mutations. 
METHODS
Patients
We retrospectively reviewed clinical and 
pathological characteristics and treatment outcomes of 
90 consecutive patients with advanced tumors harboring 
PIK3CA mutations who had been referred to the Clinical 
Center for Targeted Therapy at The University of Texas 
MD Anderson Cancer Center (MD Anderson) starting 
in October 2008. To define distinguishing features of 
advanced cancers with PIK3CA mutations, we selected a 
control group of 180 patients with wild-type (wt) PIK3CA 
advanced cancers matched in a 2:1 ratio by tumor type, 
gender, and age (+/- 5 years) to patients with PIK3CA 
mutations referred to the MD Anderson Clinical Center for 
Targeted Therapy (CCTT) during the same period of time. 
Data were collected from transcribed notes and 
radiology reports in the electronic medical record and 
other source documentation. Registering patients in the 
database, pathology assessment, and mutation analysis 
were performed at MD Anderson. The study and all 
treatments were conducted in accordance with the 
guidelines of the MD Anderson Institutional Review 
Board.
Tissue samples and mutation analyses
PIK3CA, KRAS, NRAS, and BRAF mutations were 
investigated in archival formalin-fixed, paraffin-embedded 
tissue blocks or material from primary or metastatic 
lesions obtained from diagnostic and/or therapeutic 
procedures. All histologies were centrally reviewed 
at MD Anderson. Mutation testing was performed in 
the Clinical Laboratory Improvement Amendment–
certified Molecular Diagnostic Laboratory within the 
Division of Pathology and Laboratory Medicine at MD 
Anderson. DNA was extracted from microdissected 
paraffin-embedded tumor sections and analyzed using 
a polymerase chain reaction-based DNA sequencing 
method for PIK3CA mutations in codons 532-554 of 
exon 9 (helical domain) and codons 1011-1062 of exon 
20 (kinase domain). Analysis included the mutation hot 
spot region of the PIK3CA proto-oncogene denoted by 
Sanger sequencing, following amplification of 276 bp and 
198 bp amplicons, respectively, utilizing primers designed 
by the MD Anderson Molecular Diagnostic Laboratory. 
Whenever possible, in addition to PIK3CA, mutation 
analysis was done for KRAS and NRAS codons 12, 13, and 
61 mutations, and BRAF codons 595-600 mutations of 
exon 15 by pyrosequencing, as previously described.[19] 
Treatment
Prior to being treated with Phase I agents, patients 
typically received the US Food and Drug Administration 
(FDA)-approved therapy.  If available, we collected data 
from the last FDA-approved therapy in addition to the 
Phase I therapy given in the CCTT. For patients with 
PIK3CA mutations, data were recorded for treatment 
received that included PI3K/AKT/mTOR inhibitors. For 
wt PIK3CA patients, data from the best phase I therapy 
were recorded. The response outcome was measured by 
partial [PR] or complete response [CR] or the absence of 
PR/CR as well as the duration of progression-free survival 
[PFS] and overall survival (OS). [20]
Statistical analysis
Patient characteristics were summarized using 
descriptive statistics. Response to treatment (PR or CR) 
was evaluated using Response Evaluation Criteria in 
Solid Tumors (RECIST 1.0).[20] PFS was defined as the 
interval from initiation of the selected phase I treatment 
to disease progression or death. Patients who were alive 
and not progressing were censored at the date of the 
last follow-up. Overall survival (OS) was defined as the 
interval from diagnosis to death and OS on phase I therapy 
(OS-Ph1) was defined as the interval between recorded 
initiation of the systemic phase I treatment to death. 
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Table 1: Patient characteristics
Variable Number (%) PIK3CA mutation (%)
wild-type 
PIK3CA (%) P value
All 270 (100) 90 (100) 180 (100) Not applicable
Gender
    Man 102 (38) 34 (38) 68 (38) 1.00‡
    Women 168 (62) 56 (62) 112 (62)
Age
    </= 50 years 80 (30) 26 (29) 54 (30) 0.89‡
    >50 years 190 (70) 64 (71) 126 (70)
Ethnicity
    Caucasian 213 (79) 67 (74) 146 (81) 0.12
    African-American 25 (9) 13 (14) 12 (7)
    Hispanic 18 (7) 4 (5) 14 (8)
    Asian 14 (5) 6 (7) 8 (4)
Smoking History
    Past and current smokers 113 (42) 35 (39) 78 (43) 0.52
    Non-smokers 157 (58) 55 (61) 102 (57)
History of deep vein thrombosis 
    Yes 53 (20) 24 (27) 29 (16) 0.05
    No 217 (80) 66 (73) 151 (84)
Prior therapies
    </= 3 143 (53) 52 (58) 91 (51) 0.30
    >3 127 (47) 38 (42) 89 (49)
Site of Primary Tumor
    Colorectal 72 (27) 24 (27) 48 (27) 1.00‡
    Breast 45 (17) 15 (17) 30 (17)
    Ovarian 33 (12) 11 (12) 22 (12)
    Endometrial 27 (10) 9 (10) 18 (10)
    Head & neck: squamous 24 (9) 8 (9) 16 (9)
    Cervical: squamous 18 (7) 6 (7) 12 (7)
    Non-small cell lung 12 (4) 4 (4) 8 (4)
    Other 39 (14) 13 (14) 26 (14)
Metastases
    Lungs 168 (62) 59 (66) 109 (61) 0.51
    Liver 168 (62) 55 (61) 113 (63) 0.79
    Brain 34 (13) 10 (11) 24 (13) 0.70
    Bones 89 (33) 25 (28) 64 (36) 0.22
Mutations
   KRAS mutated* 53 (25) 25 (34) 28 (21) 0.047
   KRAS wild-type* 155 (75) 49 (66) 106 (79)
   NRAS mutated** 3 (3) 1 (3) 2 (3) 1.00
   NRAS wild-type** 92 (97) 31 (97) 61 (97)
   BRAF mutated¶ 15 (8) 7 (11) 8 (7) 0.41
   BRAF wild-type¶ 164 (92) 58 (89) 106 (93)
 RAS (K- or N-) or BRAF mutated¶¶ 71 (54) 33 (66) 38 (46) 0.03
 RAS (K- or N-) and BRAF wild-type¶¶ 61 (46) 17 (34) 44 (54)
‡Patients with PIK3CA mutations and controls with wild-type PIK3CA were matched by tumor type, 
gender, and age (+/- 5 years). Therefore, differences cannot be expected  
*Tested for KRAS, n=208 (PIK3CA mutation, n=74; wild-type PIK3CA, n=134) 
**Tested for NRAS, n=95 (PIK3CA mutation, n=32; wild-type PIK3CA, n=63)
¶ Tested for BRAF, n=179 (PIK3CA mutation, n=65; wild-type PIK3CA, n=114)
¶¶ Tested for RAS (K- or N-) or BRAF, n=132 (PIK3CA mutation, n=50; wild-type PIK3CA, n=82). Since 
mutations in KRAS, NRAS, BRAF are considered to be mutually exclusive, patients with mutations or 
patients tested negative for all three mutations were included in the analysis 
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Patients who were alive were censored at the date of the 
last follow-up. Distant metastasis-free survival (DMFS) 
was defined as the interval from diagnosis to development 
of metastatic disease. The probabilities of PFS, OS, OS-
Ph1, and DMFS were estimated using the method of 
Kaplan and Meier and the time-to-event endpoints were 
compared among subgroups using the log-rank test.[21, 
22] 
Associations between PIK3CA mutation status 
and categorical variables (ethnicity, biopsy/tissue site, 
metastatic site, history of deep vein thrombosis [DVT], 
history of smoking, KRAS mutation, NRAS mutation, 
BRAF mutation, PR/CR status after last FDA-approved 
therapy, PR/CR status after PI3K/AKT/mTOR targeted 
phase I therapy in PIK3CA-mutant patients, or status 
after the best phase I therapy in wt PIK3CA patients) 
were assessed using Fisher’s exact test. PR/CR rate to 
prior vs. current therapies in matched paired subjects was 
assessed using McNemar’s test. In addition, univariate 
and multivariate logistic regression models were fit to 
assess the associations between PIK3CA mutations and 
other categorical variables. A Cox regression model was 
applied to assess the effect of covariates on time-to-event 
endpoints. All tests were two-sided, and a P value less than 
0.05 was considered statistically significant. All statistical 
analyses were carried out using SPSS 17 computer 
software (SPSS Chicago, IL) and R version 2.15.0 (R 
Foundation for Statistical Computing). 
RESULTS
Patient characteristics 
A total of 270 patients with diverse advanced 
cancers consisting of 90 patients with PIK3CA mutations 
and 180 controls with wt PIK3CA (matched by tumor 
type, gender, and age) were analyzed and their clinical 
and pathologic characteristics are listed in Table 1. Most 
patients (79%) were white and women (62%). The median 
age was 56 years (range, 16-83) and patients received 
the median number of 3 prior therapies (range, 0-12). 
The most prevalent tumor types were colorectal cancer 
(27%), breast cancer (17%), ovarian cancer (12%) and 
endometrial cancer (10%). Lung and/or liver metastases 
were found in 62% of patients. Brain metastases were 
found in 13% of patients. Of the 208 patients tested for 
KRAS, 53 (25%) had a mutation; of the 95 tested for 
NRAS, 3 (3%) had a mutation; and of the 179 tested for 
BRAF, 15 (8%) had a mutation. When analyzing tested 
MAPK mutations, of the 132 patients tested for KRAS, 
NRAS, and BRAF mutation status (patients were selected 
for analyses if they had a mutation in KRAS, or NRAS, or 
BRAF since they are known to be mutually exclusive or if 
they were tested negative for all 3 oncogenes), 71 (54%) 
had KRAS, NRAS or BRAF mutations. 
Mutation types
Of the 90 patients with PIK3CA mutations, 56 (62%) 
had mutations in exon 9 coding for the helical domain, 33 
(37%) in exon 20 coding for the kinase domain, and 1 
(1%) had a dual mutation in exons 9 and 20. The most 
Table 2: Types of PIK3CA, KRAS, 
NRAS and BRAF mutations
Mutation type N (%)
PIK3CA mutation 90 (100)
    E542K 16  (18)
    E542V 1 (<3)
    E545K 31 (34)
    E545G 2 (<3)
    Q546K 2 (<3)
    S553N 1 (<3)
    P539R, E545A 1 (<3)
    E545K, D549H 1 (<3)
    Exon 9 deletion 1 (<3)
    E545A, H1047Y 1 (<3)
    R1023Q 1 (<3)
    M1043I 2 (<3)
    M1043V 2 (<3)
    D1045N 1 (<3)
    H1047L 4 (4)
    H1047R 20 (22)
    G1049R 3 (3) 
KRAS* mutation 53 (100)
    G12A 7 (13) 
    G12C 4 (8)
    G12D 14 (26)
    G12F 1 (<3)
    G12R 3 (6)
    G12S 2 (4)
    G12V 10 (19)
    G13D 5 (9)
    Q61H 2 (4)
    Q61L 1 (<3)
   Not specified 4 (8)
NRAS** mutations 3 (100)
    G13D 1 (33)
    Q61K 1 (33)
    Q61R 1 (33)
BRAF¶ 15 (100)
    V600E 11 (73)
    V600K 3 (20)
    V600R 1 (7)
*Tested for KRAS, n=208, **Tested for NRAS, 
n=95, ¶ Tested for BRAF, n=179
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frequent mutation types were E545K (1633G>A) in 31 
(34%) patients, followed by mutated H1047R (3140A>G) 
in 20 (22%) patients and E542K (1624G>A) mutations in 
16 (18%) patients (Table 2).
Of the 53 patients with KRAS mutations, 14 
(26%) had a G12D mutation (35G>A), 10 (19%) a 
G12V mutation (35G>T), 7 (13%) had a G12A mutation 
(35G>C), 5 (9%) had a G13D mutation (38G>A) and 17 
(32%) had other mutations (Table 2). 
Of the 3 patients with NRAS mutations, 1 (33%) had 
a G13D mutation (38G>A), 1 (33%) had a Q61K mutation 
(181C>A) and 1 (33%) had a Q61R mutation (182A>G) 
(Table 2).
Of the 15 patients with BRAF mutations, 11 (73%) 
had a V600E mutation (1799_1800TG>AA), 3 (20%) a 
V600K mutation (1798_1799GT>AA), and 1 (7%) a 
V600R mutation (1798_1799GT>AG) (Table 2). 
For KRAS, NRAS, and BRAF mutations, no patient 
had more than one type of mutation within each gene, 
which is not surprising since these mutations are known 
to be mutually exclusive.[13, 23] 
Clinical and molecular features associated with 
PIK3CA mutations
Patients with PIK3CA mutations (n=90) compared 
to patients with wt PIK3CA (n=180) had a trend to 
a higher incidence of DVT (24/90 [27%] vs. 29/180 
[16%], p=0.05), higher prevalence of KRAS mutations 
(25/74 [34%] vs. 28/134 [21%], p=0.047), and a higher 
prevalence of mutations in the MAPK pathway (KRAS, 
NRAS, or BRAF mutations) (33/50 [66%] vs. 38/82 [46%], 
p=0.03) (Table 1).  There was no difference with respect 
to ethnicity, smoking history, number of prior therapies, 
biopsy/tissue site, and the occurrence of lung, liver, bone, 
and brain metastases between patients with and without 
PIK3CA mutations (Table 1). The multivariate regression 
model, which included MAPK mutation status and history 
of DVT, confirmed that patients with PIK3CA mutations 
had a higher prevalence of MAPK mutations (odds ratio 
Table 3: Outcomes in patients with PIK3CA mutations and wild-type PIK3CA patients
Cancer Outcome PIK3CA mutation wild-type PIK3CA OR or HR (95% CI) P value
All PR/CR last FDA 5/59 (8%) 6/138 (4%) OR 2.04 (95% CI 0.60-6.96) 0.31
PR/CR Phase I 10/56 (18%) 12/152 (8%) OR 2.74 (95% CI 1.07.-7.01) 0.045
PFS on last 
FDA (95% CI) 
3.0 months 
(95% CI 2.6-3.4)
3.2 months (
95% CI 2.5-3.9)
HR 1.01 
(95% CI 0.80-1.50) 0.55
PFS on Phase I 
(95% CI)
2.0 months 
(95% CI 1.4-2.6)
3.7 months 
(95% CI 3.2-4.2)
HR 1.10 
(95% CI 0.78-1.56) 0.59
DMFS (95% CI) 12.3 months (95% CI 7.5-17.1)
18.8 months 
(95% CI 14.5-23.1)
HR 1.08 
(95% CI 0.77-1.53) 0.64
OS (95% CI) 50.4 months (95% CI 36.2-64.6)
55.2 months 
(95% CI 46.7-63.7)
HR 1.07 
(95% CI 0.77-1.47) 0.70
OS-Ph1 (95% CI) 6.6 months (95% CI 3.9-9.3)
8.6 months 
(95% CI 7.1-10.1)
HR 1.49 
(95% CI 1.04-2.14) 0.03
Colorectal PR/CR last FDA (n=55) 1/18 (6%) 0/37 (0%) NA 0.34
PR/CR Phase I 
(n=47) 0/14 (0%) 0/33 (0%) NA NA
PFS on last FDA 2.8 months (95% CI 1.6-4.0)
4.3 months 
(95% CI 3.3-5.3)
HR 1.62 
(95% CI 0.90-2.92) 0.10
PFS on Phase I 1.8 months (95% CI 1.5-2.1)
3.8 months 
(95% CI 3.5-4.1)
HR 1.86 
(95% CI 0.93-3.73) 0.07
DMFS 15.2 months (95% CI 5.3-25.1)
18.8 months 
(95% CI 4.4-33.2)
HR 0.99 
(95% CI 0.43-2.29) 1.00
OS 45.1 months (95% CI 36.3-53.9)
54.0 months 
(95% CI 33.2-74.8)
HR 1.13 
(95% CI 0.62-2.06) 0.70
OS-Ph1 3.6 months (95% CI 2.5-4.7)
10.3 months 
(95% CI 6.6-14.0)
HR 3.05 
(95% CI 1.51-6.18) 0.001
Abbreviations: CI, confidence interval; FDA, Food and Drug Administration; HR, hazard ratio; NA, not applicable; 
OR, odds ratio; PR/CR, partial or complete response; PFS, progression-free survival; DMFS, distant metastases-free 
survival; OS-Ph1, overall survival on phase I therapy; OS, overall survival from diagnosis 
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[OR] 2.19, 95% confidence interval [CI] 1.05-4.59, 
p=0.04).   
Disease-specific subanalyses showed a trend toward 
an association between PIK3CA and KRAS mutations in 
colorectal cancer (17/24 [71%] vs. 21/44 [48%]; p=0.08) 
and associations between PIK3CA mutations and KRAS 
mutations (6/17 [35%] vs. 2/28 [7%], p=0.04) and MAPK 
mutations (8/13 [62%] vs. 2/15 [13%], p=0.02) in ovarian 
and endometrial cancers combined.
In addition, in all tumor types we analyzed clinical 
and molecular associations separately for PIK3CA 
mutations in exon 9 (helical domain) and exon 20 
(kinase domain), and found that PIK3CA mutations in 
exon 9 compared to others (wt PIK3CA, PIK3CA exon 
20 mutations) had a trend toward an association with 
simultaneous KRAS mutations (17/46 [37%] vs. 36/162 
[22%]; p=0.05), had a trend toward association with BRAF 
mutations (6/42 [14%] vs. 9/137 [7%]; p=0.12), and was 
significantly associated with MAPK mutations (23/33 
[70%] vs. 48/99 [48%]; p=0.04).   PIK3CA mutations in 
exon 20 compared to others (wt PIK3CA, PIK3CA exon 
9 mutations) were not associated with KRAS mutations 
(8/28 [29%] vs. 45/180 [25%]; p=0.65), BRAF mutations 
(1/23 [7%] vs. 14/156 [13%]; p=0.70), or MAPK 
mutations (10/17 [59%] vs. 61/115 [53%]; p=0.80). 
In addition, PIK3CA mutations in exon 9 compared to 
others demonstrated a trend toward an association with a 
history of DVT (16/56 [29%] vs. 37/214 [17%]; p=0.09). 
There were no other associations with any other assessed 
characteristics (ethnicity, smoking history, number of prior 
therapies, biopsy/tissue site, and the occurrence of lung, 
liver, bone, and brain metastases).   
Treatment outcomes with respect to PIK3CA 
mutation status
We analyzed PR/CR rates from the last FDA-
approved treatment in 197 patients with available data 
and found no statistically significant differences between 
patients with PIK3CA mutations and wt PIK3CA patients 
(5/59 [8%] vs. 6/138 [4%], p=0.31) (Table 3). In contrast, 
in 208 patients who received phase I systemic therapy, 
those with PIK3CA mutations treated with a phase I 
therapy targeting the PI3K/AKT/mTOR pathway had a 
higher PR/CR rate than wt PIK3CA patients treated with 
their best phase I therapy (10/56 [18%] vs. 12/152 [8%], 
p=0.045). We also analyzed PR/CR rate following phase 
I therapy separately for patients with exon 9 and those 
with exon 20 PIK3CA mutations. Patients with PIK3CA 
exon 9 mutations showed a trend toward a higher PR/
CR rate to the phase I therapy with a PI3K/AKT/mTOR 
inhibitor than patients with wt PIK3CA treated with their 
best phase I therapy (4/30 [13%] vs. 6/138 [4%], p=0.08). 
Patients with PIK3CA exon 20 mutations had a higher PR/
CR rate after phase I therapy with a PI3K/AKT/mTOR 
inhibitor compared to patients with wt PIK3CA treated 
with their best phase I therapy (6/25 [24%] vs. 6/138 [4%], 
p=0.004). In addition, we analyzed PR/CR rate sfrom 
the phase I therapy separately for patients with the most 
frequent mutations: E545K (n=31), H1047R (n=20), and 
E542K (n=16). While there was no difference in PR/CR 
rates in patients with E545K or E542K mutations, patients 
with H1047R treated with a PI3K/AKT/mTOR inhibitor 
compared to wt PIK3CA treated with their best phase I 
therapy demonstrated higher PR/CR rates(6/16 [38%] vs. 
12/152 [8%]; p=0.003). 
We next analyzed PFS after the last FDA-approved 
therapy (n=197) and phase I systemic therapy (n=208) 
(Table 3). There was no significant difference in median 
PFS following the last FDA-approved therapy between 
patients with PIK3CA mutations (3 months, 95% CI 2.6-
3.4) and wt PIK3CA (3.2 months, 95%CI 2.5-3.9, p=0.55). 
Similarly, there was no significant difference in median 
PFS after treatment with a phase I therapy targeting the 
PI3K/AKT/mTOR pathway in PIK3CA-mutant patients 
(2 months, 95% CI 1.4-2.6) versus treatment with the 
best systemic phase I therapy in wt PIK3CA patients 
(3.7 months, 95%CI 3.2-4.2, p=0.59). We also analyzed 
PFS from the phase I therapy separately for patients with 
exon 9 and exon 20 PIK3CA mutations. Patients with 
PIK3CA exon 9 mutations did not have a significantly 
different median PFS on phase I therapy compared to 
patients with wt PIK3CA (2 months [95%CI 1.9-2.1] vs. 
3.7 months [95%CI 3.2-4.2], p=0.41). Similarly, patients 
with PIK3CA exon 20 mutations had no significantly 
different median PFS after phase I therapy compared to 
patients with wt PIK3CA (1.9 months [95%CI 0.8-3.0] 
vs. 3.7 months [95%CI 3.3-4.1], p=0.77). Patients with 
H1047R mutations compared to wt PIK3CA did not have 
a significantly different median PFS (5.7 months [95%CI 
0.9-10.5] vs. 3.7 months [95%CI 3.2-4.2], p=0.26).  
Next, we performed paired analysis in 143 patients 
who had available data for treatment with the last FDA-
approved therapy and who then received subsequent phase 
I systemic therapy to compare PR/CR rate and PFS in 
these subgroups. Patients with PIK3CA mutations had a 
similar PR/CR rate in response to treatment with phase 
I therapies targeting the PI3K/AKT/mTOR pathway than 
to their previous FDA-approved therapy (5/36 [14%] vs. 
2/36 [6%], p=0.38) (Table 4). There was no statistically 
significant difference in a median PFS on the last FDA-
approved therapy (3.6 months, 95% CI 2.8-4.4) or phase I 
therapy targeting PI3K/AKT/mTOR (2.8 months, 95%CI 
1.3-4.3) in patients with PIK3CA mutations (p=0.60). 
Patients with wt PIK3CA had a similar PR/CR rate to the 
best phase I and the last FDA-approved therapies (6/107 
[6%] vs. 7/107 [7%], p=1.00). There was no statistically 
significant difference in median PFS after the last FDA-
approved therapy (3.5 months, 95% CI 2.7-4.3) and after 
the best phase I therapy (3.6 months, 95%CI 3.1-4.4.1) in 
patients with PIK3CA mutations (p=0.37). 
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Finally we analyzed OS (measured from diagnosis), 
OS-Ph1 (measured from recorded phase I therapy), and 
DMFS (measured from diagnosis to metastatic disease) 
for patients with PIK3CA mutations and wt PIK3CA 
patients (Table 3). Patients with PIK3CA mutations had 
a similar median OS (50.4 months, 95% CI 36.2-64.6) as 
patients with wt PIK3CA (55.2 months, 95% CI 46.7-63.7, 
p=0.70). In 142 patients who were initially diagnosed 
with localized disease, those with PIK3CA mutations had 
a numerically shorter DMFS (12.3 months, 95% CI 7.5-
17.1) than patients with wt PIK3CA (18.8 months, 95% 
CI 14.5-23.1, p=0.6). In 208 patients who received phase 
I therapy, those with PIK3CA mutations had a shorter 
median Ph1-OS (6.6 months, 95% CI 3.9-9.3) than 
patients with wt PIK3CA (8.6 months, 95% CI 7.1-10.1, 
p=0.03).
Colorectal cancer was the largest tumor-specific 
subgroup, consisting of 24 patients with PIK3CA 
mutations and 48 matched wt PIK3CA controls. We 
therefore performed subanalysis on this histology. 
PIK3CA mutations were most frequent in exon 9 (16/24 
[67%]) (Supplementary Table 1). PIK3CA mutations 
were not significantly associated with any specific clinical 
characteristics, although there was a trend to a lower 
prevalence of liver metastases compared to patients 
with wt PIK3CA (16/24 [67%] vs. 40/48 [83%], p=0.14) 
(Supplementary Table 2). In patients tested for KRAS 
mutations, those with PIK3CA mutations compared 
to wt PIK3CA demonstrated a trend to having a higher 
prevalence of KRAS mutations (17/24 [71%] vs. 21/44 
[48%]; p=0.08) (Supplementary Table 2). In a separate 
analysis, PIK3CA exon 9 mutations compared to others 
had a trend to a higher frequency of KRAS mutations 
(12/16 [75%] vs. 26/52 [50%]; p=0.09), whereas PIK3CA 
exon 20 mutations compared to others showed no 
association with KRAS mutations (5/8 [63%] vs. 33/60 
[55%]; p=1.00).
There was no significant difference between 
colorectal cancer patients with PIK3CA mutations and wt 
PIK3CA in PR/CR rate to the last line of FDA-approved 
therapy (1/18 [6%] vs. 0/37 [0%]; p=0.34) (Table 3). 
Patients with PIK3CA mutations had no response to PI3K/
AKT/mTOR-targeted phase I therapies and, similarly, 
wt PIK3CA patients did not respond to the best phase I 
therapy (0/14 [0%] vs. 0/33 [0%]; p=1.00).  
Colorectal cancer patients with PIK3CA mutations 
compared to wt PIK3CA demonstrated a trend to a shorter 
median PFS to the last FDA-approved therapy (2.8 months 
[1.6-4.0] vs. 4.3 months [3.3-5.3]; p=0.10) (Table 3). 
Similarly, patients with PIK3CA mutations treated with 
a PI3K/AKT/mTOR targeted therapy compared to wt 
PIK3CA patients treated with their best phase I therapy 
showed a trend to a shorter median PFS (1.8 months [1.5-
2.1] vs. 3.8 months [3.5-4.1]; p=0.07).
A paired analysis of colorectal cancer patients for 
whom we had data on the last FDA-approved therapy and 
phase I therapy (PIK3CA mutations, n=10; wt PIK3CA, 
n=25), there was no response noted (Table 4). PIK3CA 
mutant patients had a significantly longer PFS on the last 
FDA-approved therapy compared to phase I PI3K/AKT/
mTOR targeted therapy (3.7 months [2.0-5.4] vs. 1.7 
months [1.2-2.2]; p=0.01). In wt PIK3CA patients, there 
was no significant difference in median PFS on the last 
FDA-approved therapy compared to best phase I therapy 
(5 months [4.1-5.9] vs. 3.9 months [3.2-4.6], p=0.34). 
Finally, there was no significant difference in OS, 
OS-Ph1, and DMFS between colorectal cancer patients 
with PIK3CA mutations and wt PIK3CA (Table 3).
DISCUSSION
In this study of 90 patients with PIK3CA mutations 
and 180 wt PIK3CA controls (matched by tumor type, 
gender, and age) we identified having a history of DVT as 
the only clinical characteristic potentially associated with 
PIK3CA mutations. However, this association was not 
confirmed by multivariate analysis. None of the clinical 
characteristics including ethnicity, the site of metastases, 
Table 4: Paired analysis of treatment outcomes on last FDA-approved and phase I therapy 
Patients Outcome FDA approved Phase I P value
All PIK3CA mutations PR/CR 2/36 (6%) 5/36 (14%) 0.38
PFS 3.6 months (95% CI 2.8-4.4) 2.8 months (95% CI 1.3-4.3) 0.60
All wt PIK3CA PR/CR 6/107 (6%) 7/107 (7%) 1.00
PFS 3.5 months (95% CI 2.7-4.3) 3.6 months (95% CI 3.1-4.1) 0.37
Colorectal PIK3CA mutations PR/CR 0/10 (0%) 0/10 (0%) 1.00
PFS 3.7 months (95% CI 2.0-5.4) 1.7 months (95% CI 1.2-2.2) 0.01
Colorectal wt PIK3CA PR/CR 0/25 (0%) 0/25 (0%) 1.00
PFS 5.0 months (95% CI 4.1-5.9) 3.9 months (95% CI 3.2-4.6) 0.34
Abbreviations: CI, confidence interval; FDA, Food and Drug Administration; PR/CR, partial or complete response; 
PFS, progression-free survival; wt, wild-type
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smoking history, number of prior therapies, OS, OS-Ph1, 
DMFS was associated with PIK3CA status. 
In agreement with previous reports, when assessing 
individuals for MAPK mutations we noted the association 
between PIK3CA and MAPK mutations (66% vs. 46%, 
p=0.03) and between PIK3CA and KRAS mutations 
(34% vs. 21%, p=0.047).[13, 14] In disease-specific sub-
analyses, also in agreement with previous reports, there 
was a trend toward an association between PIK3CA and 
KRAS mutations in colorectal cancer (71% vs. 48%, 
p=0.08); associations between PIK3CA and KRAS (35% 
vs. 7%, p=0.04), and PIK3CA and MAPK mutations (62% 
vs. 13%, p=0.02) in ovarian and endometrial cancers.[13, 
14] We also looked for associations linked to mutations 
in exon 9 and exon 20, which account for more than 
80% of PIK3CA mutations.[24] Overall, PIK3CA exon 
9 mutations were associated with simultaneous MAPK 
mutations (70% vs. 48%; p=0.04), showed a trend toward 
association with simultaneous KRAS mutations (37% 
vs. 22%; p=0.05), and albeit a weaker trend toward 
association with BRAF mutations (14% vs. 7%; p=0.12), 
whereas PIK3CA exon 20 mutations were not associated 
with any mutations in the MAPK pathway. This finding is 
consistent with previous reports from our group and others 
in colorectal cancer and other tumor histologies.[13, 14] 
Oncogenic mutations often point to the presence 
of a therapeutic target that might be amenable to directed 
therapeutic intervention. For example, KIT mutations 
render patients with gastrointestinal stromal tumor 
sensitive to KIT tyrosine kinase inhibitors (TKIs), EGFR 
mutations render patients with NSCLC sensitive to EGFR 
TKIs, a EML4-ALK fusion renders patients with NSCLC 
sensitive to ALK inhibitors, and BRAF mutations increase 
the sensitivity of melanoma patients to BRAF inhibitors.
[25-28] We reported increased PR/CR rates in response 
to PI3K/AKT/mTOR inhibitors in patients with PIK3CA 
mutations compared to wt PIK3CA treated in early phase 
clinical trials.[8] In the current study, we retrospectively 
evaluated treatment outcomes (PR/CR rate, PFS) on the 
last FDA-approved therapy and phase I therapy (therapy 
targeting PI3K/AKT/mTOR pathway in patients with 
PIK3CA mutations or best phase I therapy [defined by 
CR/PR or longest PFS] in patients with wt PIK3CA). 
Overall, there was no difference in PR/CR rate (8% vs. 
4%; p=0.31) and PFS (3.0 months vs. 3.2 months, p=0.55) 
to the last FDA-approved therapy between patients with 
PIK3CA mutations and wt PIK3CA, but patients with 
PIK3CA mutations had a higher PR/CR rate to phase I 
therapy with PI3K/AKT/mTOR inhibitors (18% vs. 8%; 
p=0.045), which did not, however, translate to a longer 
PFS (2.0 months vs. 3.7 months; p=0.59) compared to wt 
PIK3CA patients treated with their best phase I therapy. 
In the paired analysis, which included only patients who 
had available data from treatment with both the last 
FDA-approved therapy and phase I therapy, we found 
no difference in PR/CR rates and PFS in patients with 
PIK3CA mutations and wt PIK3CA.  The explanation 
for this might be because PI3K/AKT/mTOR targeting 
therapies are effective in only a subset of patients. In 
NSCLC, specific EGFR mutations such as exon 19 
deletions or exon 21 mutations (L858R), render tumors 
sensitive to EGFR TKIs, whereas an exon 20 mutation 
(T790M) is associated with therapeutic resistance.
[29] A similar scenario is possible for other oncogenic 
mutations. Indeed, in our current study we noticed that 
patients with H1047R PIK3CA mutations compared to 
patients with wt PIK3CA had an increased PR/CR rate 
(38% vs. 8%; p=0.003) to phase I therapy compared to wt 
PIK3CA patients. Another explanation might relate to the 
histological milieu of the PIK3CA mutations. Although, 
these mutations were found in a variety of cancers, the 
largest subgroup of patients had colorectal cancer. These 
patients showed a poor outcome on PI3K/AKT/mTOR, 
perhaps because of the frequent coexistence of KRAS 
mutations in this histology.[13, 14, 30]         
Finally, we investigated whether PIK3CA mutations 
have prognostic significance. For instance, EGFR 
mutations compared to wt EGFR in NSCLC are usually 
associated with improved treatment outcomes and a longer 
OS.[31] KRAS mutations in NSCLC are associated with 
poor outcomes in response to EGFR therapies.[31] In 
colorectal cancer, BRAF mutations are associated with a 
shorter survival.[13]  Consensus regarding the impact of 
PIK3CA mutations is contradictory. Some investigators 
reported better prognosis in certain cancers such as breast 
cancer with PIK3CA mutations, whereas others suggested 
that PIK3CA mutations indicate a worse prognosis in 
colorectal cancer, endometrial cancer and NSCLC.[13, 29, 
32-36] There was no significant difference in patients with 
PIK3CA mutations and wt PIK3CA in OS (from the time 
of first diagnosis; 50.4 months vs. 55.2 months; p=0.70), 
and DMFS (from time of first diagnosis to development 
of metastatic disease; 12.3 months vs. 18.8 months; 
p=0.64); however, patients with PIK3CA mutations had 
a shorter OS-Ph1 (from initiation of phase I therapy; 
6.6 months vs. 8.6 months; p=0.03). In disease-specific 
sub-analyses, we found a lower survival in patients with 
colorectal cancer and PIK3CA mutations who, compared 
to wt PIK3CA patients, experienced a shorter OS-Ph1 (3.6 
months vs. 10.3 months; p=0.001). This finding provides 
another piece of evidence suggesting that colorectal cancer 
patients with PIK3CA mutations do not do well on a PI3K/
AKT/mTOR targeted therapy. 
In conclusion, in the current study of 90 patients 
with PIK3CA mutations and 180 matched controls with wt 
PIK3CA we found that there was no PIK3CA phenotype. 
Overall, PIK3CA mutations were associated with KRAS 
and MAPK (KRAS, NRAS, BRAF) mutations.  Patients 
with PIK3CA mutations treated with PI3K/AKT/mTOR 
axis inhibitors had a PR/CR rate of 18%. This PR/CR 
rate is lower than the rate we previously reported for 
gynecologic and breast malignancies, in which the PR/
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CR rate was 30%, and may be due to the fact that the 
largest subgroup (colorectal cancer) in this paper did not 
respond well to PI3K/AKT/mTOR axis therapy even 
in the presence of PIK3CA mutations.[16]  The lack of 
response may be due to the high rate of concomitant 
MAPK mutations in colorectal cancer.  Finally, patients 
with PIK3CA H1047R mutations in exon 20 appeared to 
have the most favorable PR/CR rate, but this observation 
requires confirmation in a larger cohort of patients.
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